A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors

Trial Profile

A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs CLR 1404 I-131 (Primary)
  • Indications Brain cancer; Hodgkin's disease; Lymphoma; Neuroblastoma; Sarcoma
  • Focus Adverse reactions
  • Sponsors Cellectar Biosciences
  • Most Recent Events

    • 26 Mar 2018 Status changed from planning to not yet recruiting.
    • 19 Mar 2018 According to a Cellectar Biosciences media release, company expects to initiate this study during the second quarter of 2018.
    • 22 Jan 2018 According to a Cellectar Biosciences media release, this trial is expected to initiate in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top